ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels. The expansion phase is now open for enrollment in indications including HNSCC and PDAC.

Trial Details

NCT ID
NCT06597721
Phase
PHASE1
Sponsor
Adcendo ApS
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • ADCE-T02
Locations (sample)
  • Rogers, Arkansas, United States|36.33202,-94.11854
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • St Louis, Missouri, United States|38.62727,-90.19789
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Patients must have pathologically confirmed unresectable advanced solid tumor
  • Patients who have undergone at least one systemic therapy and have progressive disease
  • Patients must have at least one measurable lesion as per RECIST version 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →